Drug intelligence / Profile preview

SP-006

Development stage: Preclinical
Lead developer: Sunny Pharmtech
Modality: Small Molecules
Administration: Oral

Overview

SP-006 is a small molecule, sustained-release oral tablet formulation developed by Sunny Pharmtech for the prevention of organ transplant rejection. Sunny Pharmtech, a Contract Development and Manufacturing Organization (CDMO) specializing in high-potency APIs and complex drug delivery systems, is developing this product likely as a generic or an improved formulation (such as a 505(b)(2) candidate) of an existing immunosuppressant. The drug is currently in the pivotal batch stage of development, a phase in the CDMO R&D process that typically precedes bioequivalence (BE) testing and regulatory submission.

Beyond the preview

Go deeper on SP-006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SP-006.

Explore the full profile